Affinity Asset Advisors, LLC Bellus Health Inc. Transaction History

Affinity Asset Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$7.14 - $8.53 $2.2 Million - $2.62 Million	307,651 Added 53.63%	881,329 $6.35 Million
Q4 2022 Feb 13, 2023	BUY	$8.22 - $10.76 $822,665 - $1.08 Million	100,081 Added 21.13%	573,678 $4.72 Million
Q3 2022 Nov 14, 2022	SELL	$8.95 - $12.0 $176,144 - $236,172	-19,681 Reduced 3.99%	473,597 $5 Million
Q2 2022 Aug 12, 2022	SELL	$6.46 - $10.02 $689,424 - $1.07 Million	-106,722 Reduced 17.79%	493,278 $4.56 Million
Q1 2022 May 13, 2022	BUY	$5.56 - $7.99 $556,000 - $799,000	100,000 Added 20.0%	600,000 $4.13 Million
Q4 2021 Feb 11, 2022	SELL	$5.26 - $8.3 $168,477 - $265,849	-32,030 Reduced 6.02%	500,000 $4.03 Million
Q3 2021 Nov 12, 2021	BUY	$2.7 - $6.64 $626,481 - $1.54 Million	232,030 Added 77.34%	532,030 $3.27 Million
Q1 2021 May 14, 2021	BUY	$3.03 - $4.58 $908,999 - $1.37 Million	300,000 New	300,000 $1.15 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.